These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 31202702)

  • 1. Molecular mechanisms of cereblon-based drugs.
    Asatsuma-Okumura T; Ito T; Handa H
    Pharmacol Ther; 2019 Oct; 202():132-139. PubMed ID: 31202702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of thalidomide and its derivatives.
    Ito T; Handa H
    Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(6):189-203. PubMed ID: 32522938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cereblon as a primary target of IMiDs].
    Ito T; Handa H
    Rinsho Ketsueki; 2019; 60(9):1013-1019. PubMed ID: 31597822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.
    Petzold G; Fischer ES; Thomä NH
    Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology.
    Ito T; Yamaguchi Y; Handa H
    Cell Chem Biol; 2021 Jul; 28(7):987-999. PubMed ID: 34033753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Mechanisms of the Teratogenic Effects of Thalidomide.
    Asatsuma-Okumura T; Ito T; Handa H
    Pharmaceuticals (Basel); 2020 May; 13(5):. PubMed ID: 32414180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide and its metabolite 5-hydroxythalidomide induce teratogenicity via the cereblon neosubstrate PLZF.
    Yamanaka S; Murai H; Saito D; Abe G; Tokunaga E; Iwasaki T; Takahashi H; Takeda H; Suzuki T; Shibata N; Tamura K; Sawasaki T
    EMBO J; 2021 Feb; 40(4):e105375. PubMed ID: 33470442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Discovery of the target for immunomodulatory drugs (IMiDs)].
    Ito T; Ando H; Handa H
    Rinsho Ketsueki; 2016 May; 57(5):556-62. PubMed ID: 27263779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
    Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
    J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Ubiquitination-Dependent and -Independent Functions of Cereblon in Cancer and Neurological Diseases.
    Zhou L; Xu G
    J Mol Biol; 2022 Mar; 434(5):167457. PubMed ID: 35045330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
    Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
    J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein degraders - from thalidomide to new PROTACs.
    Ito T
    J Biochem; 2024 Apr; 175(5):507-519. PubMed ID: 38140952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of novel cereblon modulators and their target molecules].
    Ito T
    Rinsho Ketsueki; 2022; 63(6):573-579. PubMed ID: 35831190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.
    Fischer ES; Böhm K; Lydeard JR; Yang H; Stadler MB; Cavadini S; Nagel J; Serluca F; Acker V; Lingaraju GM; Tichkule RB; Schebesta M; Forrester WC; Schirle M; Hassiepen U; Ottl J; Hild M; Beckwith RE; Harper JW; Jenkins JL; Thomä NH
    Nature; 2014 Aug; 512(7512):49-53. PubMed ID: 25043012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4
    Sievers QL; Gasser JA; Cowley GS; Fischer ES; Ebert BL
    Blood; 2018 Sep; 132(12):1293-1303. PubMed ID: 30042095
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Fink EC; McConkey M; Adams DN; Haldar SD; Kennedy JA; Guirguis AA; Udeshi ND; Mani DR; Chen M; Liddicoat B; Svinkina T; Nguyen AT; Carr SA; Ebert BL
    Blood; 2018 Oct; 132(14):1535-1544. PubMed ID: 30064974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy.
    Costacurta M; He J; Thompson PE; Shortt J
    J Pers Med; 2021 Nov; 11(11):. PubMed ID: 34834536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Analysis of Cereblon Neosubstrates in Rabbit Embryos Using Targeted Proteomics.
    Federspiel JD; Catlin NR; Nowland WS; Stethem CM; Mathialagan N; Fernandez Ocaña M; Bowman CJ
    Mol Cell Proteomics; 2024 Jul; 23(7):100797. PubMed ID: 38866076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent topics in IMiDs and cereblon].
    Ito T; Handa H
    Rinsho Ketsueki; 2017; 58(10):2067-2073. PubMed ID: 28978850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. USP15 antagonizes CRL4
    Nguyen TV
    Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.